ISSN 1998 – 409X

REVIEW ARTICLE

Artificial Intelligence-Driven Personalized Medicine

Muneendra Madam[1], Manjula Chella[2], M. Pradeep Kumar[3]

[1]ScieGen Pharmaceuticals, New York, USA, [2]Department of Pharmaceutical Technology, Vasavi Institute of Pharmaceutical Sciences, Kadapa, Andhra Pradesh, India, [3]Department of Pharmaceutics, Vasavi Institute of Pharmaceutical Sciences, Vasavi Nagar, Peddapalli, Kadapa, Andhra Pradesh, India

Abstract

In the era of big data, healthcare systems generate enormous volumes of information ranging from genetic sequences and clinical records to real-time patient monitoring data. By applying sophisticated algorithms to genomic, proteomic, and clinical data, artificial intelligence (AI) can identify subtle patterns and correlations that inform a deeper understanding of disease mechanisms. This enables the development of highly individualized treatment plans, where therapies are tailored to the unique genetic, environmental, and lifestyle factors of each patient. Such precision medicine approaches enhance therapeutic effectiveness, minimize adverse drug reactions, and improve overall patient outcomes. Deep learning techniques accelerate the analysis of molecular structures and facilitate virtual screening, drastically reducing the time and costs traditionally associated with laboratory experimentation and clinical trials. This review explores the multifaceted ways in which AI is advancing precision medicine – improving disease risk assessment, enabling early diagnosis, and supporting adaptive treatment strategies. It also investigates AI-driven innovations in drug discovery, such as automated hypothesis generation, high-throughput screening, and predictive modeling. In addition, the review critically examines the challenges inherent to integrating AI in healthcare, including issues of data privacy, algorithmic bias, and regulatory compliance, while highlighting emerging trends and future directions such as explainable AI, quantum computing, and global regulatory frameworks that are poised to shape the next generation of medical and pharmaceutical breakthroughs.

Key words: Artificial intelligence, bioinformatics, deep learning, drug discovery, machine learning, personalized medicine, precision medicine

INTRODUCTION[1-4]

The integration of artificial intelligence (AI) into healthcare is revolutionizing both disease management and pharmaceutical development. Personalized medicine and AI-driven drug discovery represent a paradigm shift away from uniform treatments, focusing instead on therapies tailored to a patient's genetic, clinical, and lifestyle profile. This review discusses the core principles of these approaches, their current impact, and the objectives guiding this field's advancement.

DEFINING PERSONALIZED MEDICINE AND AI-DRIVEN DRUG DISCOVERY

- Personalized medicine customizes medical care based on individual genetic makeup, biomarkers, and other unique patient features, aiming to increase treatment effectiveness and reduce adverse effects
- AI-driven drug discovery leverages computational models to analyze large biological datasets, predict how drugs interact with targets, and design new compounds more efficiently than traditional methods.

AI'S IMPACT ON HEALTHCARE AND DRUG DEVELOPMENT[5-8]

- AI enables faster, more accurate diagnosis, improves disease risk assessment, and supports the development of precise therapies

Address for correspondence:
M. Pradeep Kumar,
Vasavi Institute of Pharmaceutical Sciences,
Vasavi Nagar, Sidhout (M), Kadapa - 516 247,
Andhra Pradesh, India. Mobile: +91-9966466281.
E-mail: drpradeeppharma21@gmail.com

Received: 22-06-2026
Revised: 02-08-2026
Accepted: 11-08-2026

© 2026 Author(s). This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International License (CC BY 4.0)

- In pharmaceuticals, AI automates data analysis, predicts promising compounds, and optimizes drug design, greatly accelerating research and development
- Tools like deep learning (DL), natural language processing, and neural networks aid in biomarker discovery, outcome prediction, and clinical trial design.

THE IMPORTANCE OF PRECISION MEDICINE[9]

- Precision medicine enables targeted treatments for diseases such as cancer and cardiovascular disorders by incorporating genetic and molecular data into care decisions
- AI-driven analytics help identify patients at higher risk and suggest personalized prevention or intervention strategies
- Drug repurposing, facilitated by AI, finds new applications for existing medications, reducing time and costs for bringing therapies to market.

AI TECHNIQUES IN HEALTHCARE[10]

- Machine learning (ML): Identifies disease patterns and predicts outcomes using patient data (e.g., support vector machines and clustering)
- DL: Models such as convolutional neural networks and recurrent neural networks interpret complex biomedical data, such as medical imagery and genomics
- Big data analytics: Allows rapid processing of multi-omics and patient data, supporting real-time decisions.

PRECISION MEDICINE FRAMEWORKS[11,12]

- Genomics-based therapy: AI links genetic profiles to drug response, optimizing treatment selection
- Pharmacogenomics: Predicts individual drug metabolism to minimize side effects and enhance efficacy
- Biomarker discovery: AI uncovers novel disease markers for diagnosis and therapy guidance.

DRUG DISCOVERY MODELS[13]

- Traditional approach: involves lengthy, expensive experimental phases with high attrition rates
- AI-assisted discovery: Employs predictive modeling, virtual screening, and automation to reduce costs and timelines as shown in Fig 1.

BIOINFORMATICS AND SYSTEMS BIOLOGY[14]

- Bioinformatics: Uses AI to interpret molecular data and identify therapeutic targets
- Systems biology: Integrates biological networks, using AI to predict drug interactions and optimize treatment strategies.

AI IN PERSONALIZED MEDICINE[15]

AI's role in personalized medicine spans from data analysis to treatment adaptation as shown in Fig 2.

Genomic sequencing and biomarker identification

- AI expedites the analysis of sequencing data, detecting disease-linked mutations
- Identification of biomarkers through AI supports early diagnosis and treatment stratification.

Predictive disease modeling

- AI assesses individual disease risk using genetic, environmental, and lifestyle data
- Applications include cardiovascular risk scoring and neurodegenerative disease prediction.

Personalized treatment planning

- AI customizes therapies based on patient history and real-time health data
- Adaptive models continually refine recommendations as new data is collected.

Clinical decision support systems (CDSS)

- AI-driven CDSS provide evidence-based guidance, reducing errors and optimizing care
- Notable examples include IBM Watson and Google DeepMind technologies.

Remote monitoring and adaptive therapies

- Wearable devices powered by AI monitor health metrics and detect issues in real time
- Telemedicine solutions adjust treatments dynamically in response to patient feedback.

AI IN DRUG DISCOVERY AND DEVELOPMENT

Target identification and validation

- AI analyzes biological and omics data to pinpoint new drug targets
- Tools such as CRISPR screening, when combined with AI, identify genetic factors relevant to therapy.

Compound screening and selection

- ML predicts which chemical structures are likely to succeed as drugs
- Virtual screening and molecular design are expedited by generative AI models.

Drug repurposing

- AI discovers new uses for existing drugs by analyzing molecular and clinical data
- Success stories include rapid responses to emerging diseases like COVID-19.

Pre-clinical and clinical trials

- AI automates patient recruitment and simulates drug effects to minimize reliance on animal testing
- Predictive modeling informs trial design and monitoring.

Drug formulation and optimization

- AI fine-tunes drug dosage, formulation, and delivery for maximum patient compliance and therapeutic benefit.
- Advances in nanotechnology are guided by AI to enable precise delivery.

ADVANTAGES OF AI IN HEALTHCARE

Efficiency and cost reduction

- AI shortens drug development cycles and reduces research costs by streamlining candidate screening and workflow automation.

Improved diagnosis and treatment

- Diagnostic tools powered by AI interpret medical images and genomic data with high accuracy
- Decision support systems help select the most effective, individualized treatments.

Accelerated discovery for rare diseases

- AI enables research in rare diseases, where traditional methods are often impractical
- Repurposing and advanced modeling shorten approval timelines for new therapies.

Better patient outcomes

- AI-personalized therapies minimize adverse reactions and maximize treatment effectiveness




Figure 1: Workflow of artificial intelligence-driven personalized medicine: From data acquisition to adaptive patient care

- Predictive analytics and monitoring improve early detection and response.

Reduced side effects

- AI models predict patient responses and optimize dosing to minimize harmful effects
- Pharmacovigilance systems identify and address adverse reactions in real time.

CHALLENGES AND ETHICAL CONSIDERATIONS

Data privacy and security

- The need for massive patient datasets raises concerns about privacy and data breaches




Figure 2: Comparison of traditional and artificial intelligence-assisted drug discovery timelines




Figure 3: Emerging trends shaping the future of artificial intelligence in healthcare

- Compliance with data protection laws and secure sharing solutions is essential.

Algorithmic bias

- Biases in training data can lead to unequal treatment outcomes
- Addressing data diversity and transparency is key to equitable AI-driven care.

Regulatory and compliance hurdles

- AI-driven drug development must meet stringent regulatory requirements
- Standardized guidelines for AI-based clinical trials are still evolving.

Ethical and accountability issues

- Questions remain about responsibility for AI-generated medical decisions
- Transparent oversight and ethical frameworks are necessary for trust and safety.

Integration with existing systems

- Outdated healthcare infrastructure often impedes AI adoption
- Investment in interoperability and staff training is required for successful implementation.

CASE STUDIES

- AI in cancer treatment: IBM Watson for Oncology analyzes records and literature to suggest tailored cancer therapies, although results highlight the need for ongoing model refinement
- Drug discovery for COVID-19: DeepMind's AlphaFold predicted protein structures critical for COVID-19 drug and vaccine development, demonstrating rapid, AI-driven progress during health crises
- Rare disease treatments: Companies such as BenevolentAI have used AI to repurpose existing drugs for rare conditions, accelerating discoveries for under-researched diseases.

FUTURE DIRECTIONS

Several emerging trends are expected to shape the future of AI in healthcare (Figure 3).

- Quantum computing: Quantum computing will further enhance AI's ability to model complex molecular interactions, optimizing target identification and compound design
- AI and CRISPR: AI enhances the precision of CRISPR gene editing, promising more effective and safer treatments for genetic disorders
- AI in vaccine development: AI algorithms expedite vaccine design and adaptation to new variants, as seen in the swift response to COVID-19
- Regulatory frameworks: There is a growing need for global, harmonized regulations addressing transparency, validation, and ethical use of AI in healthcare
- Explainable AI (XAI): XAI seeks to make AI decisions interpretable, fostering trust among clinicians, regulators, and patients, and ensuring ethical deployment.

CONCLUSION

AI is transforming the landscape of medicine and pharmaceuticals by enabling data-driven, individualized care and rapid, cost-effective drug development. While significant challenges remain in ethics, regulation, and integration, ongoing advancements in AI, quantum computing, and gene editing continue to unlock new potentials. Collaboration among clinicians, researchers, and policymakers is vital to ensure that AI innovations are equitable, transparent, and beneficial for all.

REFERENCES

1. Topol EJ. High-performance medicine: The convergence of human and artificial intelligence. Nat Med 2019;25:44-56.
2. Esteva A, Kuprel B, Novoa RA, Ko J, Swetter SM, Blau HM, *et al*. Dermatologist-level classification of skin cancer with deep neural networks. Nature 2017;542:115-8.
3. Zhavoronkov A, Vanhaelen Q, Oprea TI. Will artificial intelligence for drug discovery impact clinical pharmacology? ClinPharmacolTher 2020;107:780-5.
4. Rajpurkar P, Chen E, Banerjee O, Topol EJ. AI in health and medicine. Nat Med 2022;28:31-8.
5. Jumper J, Evans R, Pritzel A, Green T, Figurnov M, Ronneberger O, *et al*. Highly accurate protein structure prediction with AlphaFold. Nature 2021;596:583-9.
6. Ching T, Himmelstein DS, Beaulieu-Jones BK, Kalinin AA, Do BT, Way GP, *et al*. Opportunities and obstacles for deep learning in biology and medicine. J R Soc Interface 2018;15:20170387.
7. Beam AL, Kohane IS. Big data and machine learning in health care. JAMA 2018;319:1317-8.
8. Obermeyer Z, Emanuel EJ. Predicting the future - big data, machine learning, and clinical medicine. N Engl J Med 2016;375:1216-9.
9. Krittanawong C, Zhang H, Wang Z, Aydar M, Kitai T. Artificial intelligence in precision cardiovascular medicine. J Am Coll Cardiol 2017;69:2657-64.
10. Chen M, Hao Y, Cai Y, Wang Y, Sun Y. Artificial intelligence in healthcare: Past, present and future. Semin Cancer Biol 2021;69:144-56.
11. Lee JG, Jun S, Cho YW, Lee H, Kim GB, Seo JB, *et al*. Deep learning in medical imaging: General overview. Korean J Radiol 2017;18:570-84.
12. Mak KK, Pichika MR. Artificial intelligence in drug development: Present status and future prospects. Drug Discov Today 2019;24:773-80.
13. Topol EJ. A decade of digital medicine innovation. Sci Transl Med 2019;11:eaaw7610.
14. Nguyen NT, Nguyen TP, Nguyen TT, Van Nguyen H. Artificial intelligence in drug discovery and development: Current status and future directions. Drugs 2022;82:1273-90.
15. Yu KH, Beam AL, Kohane IS. Artificial intelligence in healthcare. Nat Biomed Eng 2018;2:719-31.

Source of Support: Nil. **Conflicts of Interest:** None declared.